Regional Analysis

Global Diabetic Ketoacidosis Treatment Market: Regional Analysis

On the basis of region, the global diabetic ketoacidosis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The rising prevalence of common chronic conditions such as diabetes and associated complications such as diabetes ketoacidosis are major burden in North America. According to the Centres for Disease Control and Prevention, till 2015, around 30 million people in the U.S. had diabetes and recorded significant increase in annual average rate of 6.3% from 2009 to 2014 of persons hospitalized due to diabetes ketoacidosis. Thus, pharmaceutical companies are focusing on direct treatment or increasing the availability of supportive treatment for diabetes ketoacidosis. For instance, in June 2020, Lexicon Pharmaceutical Inc. announced use of Zynquista (sotagliflozin) to balance the risk of diabetes ketoacidosis in adults with type-1 diabetes at the Virtual 80^th American Diabetic Association scientific session.

Moreover, there is high incidence of diabetes in Europe due to increasing fast food consumption and changing lifestyle. According to the International Diabetes Federation incidence rate of diabetes in Europe was 77% up until 2019. In this region, intravenous insulin and electrolyte fluids are highly used treatments for diabetic ketoacidosis. In 2018, the European Journal of Internal Medicine stated that basal insulin with regular insulin fusion is well effective and a primary in treatment for diabetic ketoacidosis. Thus higher use of insulin in diabetic treatment is expected to drive growth of the European diabetic treatment market during the forecast period.

Geographies covered: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.